Illinois House Bill HB1720

Illinois 2025-2026 Regular Session

• Introduced: 1/24/25
• Refer: 1/28/25

Caption

TIANEPTINE PROHIBITION ACT

Summary

HB1720 creates the Retail Sale of Tianeptine Prohibition Act, a new Illinois law that would ban the sale, offer for sale, or distribution of any product containing tianeptine beginning January 1, 2026. The bill makes an exception for tianeptine that is lawfully dispensed or prescribed by a pharmacist or other licensed health care professional. It also defines “health care professional” broadly to include persons subject to state licensure or regulation who treat human ailments, including students and residents. The bill establishes a penalty for violations as a business offense with a minimum fine of $1,500 for each violation. In practical terms, it would add a new restriction on retail and commercial sales of tianeptine products in Illinois while preserving access through legitimate medical channels. The measure is framed as a criminal-law-related consumer and public health restriction rather than a controlled-substance scheduling change.

Impact

HB1720 would create a new standalone statutory prohibition on retail tianeptine sales in Illinois, affecting retailers, distributors, and any person offering tianeptine-containing products for sale in the state. It would not bar medically authorized dispensing or prescribing, so pharmacists and licensed health care professionals would remain able to provide tianeptine where lawful. The bill would also impose a minimum civil-style business offense fine of $1,500 per violation, giving enforcement authorities a new penalty tool against commercial sellers of the substance.

Sentiment

Because there are no committee transcripts or recorded votes provided, the bill’s sentiment can only be inferred from its text and sponsor. The measure appears to reflect a precautionary, public-safety-oriented approach to restricting access to tianeptine products. The absence of recorded debate or voting history means there is no documented opposition or support in the supplied materials, but the bill’s structure suggests it is intended to address concerns about misuse or consumer harm while preserving legitimate medical use.

Contention

The main point of potential contention is the breadth of the retail ban versus the limited medical exception. Retail sellers and distributors of tianeptine products could object to a categorical prohibition and the mandatory minimum fine, especially if they view the substance as being sold in lawful consumer products. On the other hand, supporters would likely emphasize public health and consumer protection, arguing that the ban is necessary to prevent misuse and unsafe access. The definition of “health care professional” and the scope of what counts as lawful dispensing or prescribing could also raise implementation questions.